
Savara (SVRA) Stock Forecast & Price Target
Savara (SVRA) Analyst Ratings
Bulls say
Savara Inc. has recently exhibited strong financial growth potential, reflected in the increased DCF-derived price target, which was raised to $11 from $8, due to favorable updates and improved sales estimates. The projected peak annual U.S. sales for the molgramostim nebulizer solution, Molbreevi, have risen to $962 million, demonstrating a significant upward revision from previous estimates, as demand among pulmonologists appears robust. Additionally, the company anticipates a higher launch list price for Molbreevi, now estimated at $425,000, which bolsters expectations of worldwide peak sales reaching approximately $1.6 billion.
Bears say
Savara Inc. faces significant challenges that contribute to a negative outlook, primarily stemming from potential delays in regulatory approval and market entry for its pulmonary treatment, molgramostim, which could hinder sales and market share growth. Elevated research and development (R&D) and selling, general, and administrative (SG&A) expenses have also exceeded expectations, while total other income has fallen short, adding financial strain to the company's performance. Additionally, the pushback of the expected commercial launch in Japan to 2028 and a reduced probability of success from 90% to 75% further underscore concerns regarding Savara's ability to effectively penetrate key markets.
This aggregate rating is based on analysts' research of Savara and is not a guaranteed prediction by Public.com or investment advice.
Savara (SVRA) Analyst Forecast & Price Prediction
Start investing in Savara (SVRA)
Order type
Buy in
Order amount
Est. shares
0 shares